Diagnostic efficacy of [⁶⁸Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma.

IF 8.6 1区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

European Journal of Nuclear Medicine and Molecular Imaging Pub Date : 2024-11-01 Epub Date: 2024-06-25 DOI:10.1007/s00259-024-06801-y

Wenjia Zhu, Guoyang Zheng, Xinchun Yan, Meixi Liu, Xiaoyuan Li, Yuejuan Cheng, Chunmei Bai, Yushi Zhang, Li Huo

{"title":"Diagnostic efficacy of [68Ga]Ga-NY104 PET/CT to identify clear cell renal cell carcinoma.","authors":"Wenjia Zhu, Guoyang Zheng, Xinchun Yan, Meixi Liu, Xiaoyuan Li, Yuejuan Cheng, Chunmei Bai, Yushi Zhang, Li Huo","doi":"10.1007/s00259-024-06801-y","DOIUrl":null,"url":null,"abstract":"Purpose: Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [68Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [68Ga]Ga-NY104 PET/CT to identify ccRCC.Materials and methods: Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [68Ga]Ga-NY104 PET/CT.Results: A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [68Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [68Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results.Conclusions: [68Ga]Ga-NY104 PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":8.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-024-06801-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/25 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Most clear cell renal cell carcinoma (ccRCC) overexpresses carbonic anhydrase IX (CAIX). [⁶⁸Ga]Ga-NY104 is a small-molecule PET agent selectively targeting CAIX. This study aims to assess the efficacy of [⁶⁸Ga]Ga-NY104 PET/CT to identify ccRCC.

Materials and methods: Participants were prospectively recruited in the study (ClinicalTrials.gov: NCT05902377). They were further divided into two groups: group 1, patients with primary renal mass who were scheduled for surgery, group 2, patients with suspected/confirmed metastatic ccRCC. All patients underwent [⁶⁸Ga]Ga-NY104 PET/CT.

Results: A total of 47 patients (mean age, 58.8 years ± 13.5, 34 men) were recruited, including 20 patients in group 1 and 27 patients in group 2. The patient-level sensitivity, specificity, and accuracy of [⁶⁸Ga]Ga-NY104 PET scan was 62%, 33%, 58% for group 1 and 95%, 100%, 96% for group 2. [⁶⁸Ga]Ga-NY104 PET identified additional 26 disease regions in 67% (14/21) of patients that were previously unknown. The tumor uptake was correlated with immunohistochemical staining results.

Conclusions: ^{[68Ga]Ga-NY104} PET/CT has a high diagnostic efficacy for patients with metastatic ccRCC, while it might be of limited value in the diagnosis of primary ccRCC.

Abstract Image

查看原文本刊更多论文

68Ga]Ga-NY104 PET/CT 鉴别透明细胞肾细胞癌的诊断效果。

目的：大多数透明细胞肾细胞癌（ccRCC）过度表达碳酸酐酶 IX（CAIX）。[68Ga]Ga-NY104 是一种选择性靶向 CAIX 的小分子 PET 剂。本研究旨在评估[68Ga]Ga-NY104 PET/CT识别ccRCC的有效性：该研究前瞻性地招募了参与者（ClinicalTrials.gov：NCT05902377）。他们被进一步分为两组：第一组是计划接受手术的原发性肾肿块患者，第二组是疑似/确诊转移性 ccRCC 患者。所有患者均接受了[68Ga]Ga-NY104 PET/CT检查：第一组患者[68Ga]Ga-NY104 PET扫描的敏感性、特异性和准确性分别为62%、33%和58%，第二组患者[68Ga]Ga-NY104 PET扫描的敏感性、特异性和准确性分别为95%、100%和96%。肿瘤摄取与免疫组化染色结果相关：结论：[68Ga]Ga-NY104 PET/CT对转移性ccRCC患者有很高的诊断效果，但对原发性ccRCC的诊断价值可能有限。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Nuclear Medicine and Molecular Imaging 医学-核医学

CiteScore

15.60

自引率

9.90%

发文量

392

审稿时长

3 months

期刊介绍： The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.